BYD Company Limited
002594
Contemporary Amperex Technology
300750
Orient Group Incorporation
600811
4
Kweichow Moutai
600519
5
Ping An Insurance
601318
CN Stock MarketDetailed Quotes
000739 Apeloa Pharmaceutical
- 17.35
- -0.18-1.03%
Market Closed Mar 5 15:00 CST
20.29BMarket Cap18.90P/E (TTM)
17.66High17.21Low114.02KlotVolume17.48Open17.53Pre Close198.17MTurnover0.98%Turnover Ratio19.21P/E (Static)1.17BShares18.9652wk High3.08P/B20.28BFloat Cap11.9252wk Low19.28Limit Up1.17BShs Float40.98Historical High15.78Limit Down2.57%Amplitude-1.06Historical Low0.32Dividend TTM17.38Avg Price58.70KlotAsk1.83%Div YieldTTM100Lot Size53.10KlotBid
Apeloa Pharmaceutical News
Apeloa PharmaceuticalLtd (SZSE:000739) Has A Pretty Healthy Balance Sheet
Apeloa Pharmaceutical (000739.SZ): has not yet repurchased the company's shares.
On March 3, Gelonghui reported that Apeloa Pharmaceutical (000739.SZ) announced that as of February 28, 2025, the company has not yet repurchased its shares through the repurchase special Account via centralized bidding Trade.
China Merchants: The surge in ADC research and development is driving a significant increase in outsourcing demand, and the ADC CDMO market is thriving.
The surge in ADC research and development has driven a significant increase in outsourcing demand, with strong market demand for ADC CDMO. Currently, the market shows a dual drive of capacity expansion and technological iteration.
Apeloa Pharmaceutical Plans Share Buyback of Up to 150 Million Yuan
Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Apeloa Pharmaceutical (000739.SZ): Has not yet started the research and development of oral formulations of Semaglutide.
Glonghui, January 20 - Apeloa Pharmaceutical (000739.SZ) stated on the investor interaction platform that, so far, the company has not started the research and development of oral formulations of semaglutide.
Apeloa Pharmaceutical (000739.SZ): Currently not involved in utilizing AI Q&A training to assist in the Medical Services related fields.
On January 17, Gelonghui reported that Apeloa Pharmaceutical (000739.SZ) stated on the investor interaction platform that currently, the company's exploration and application of AI technology mainly focus on pharmaceutical manufacturing and Operation management, assisting in the improvement of the company's manufacturing automation, digitization level, and operational efficiency; it does not currently involve the use of AI question-and-answer training to assist in the field of Medical Services.
Apeloa Pharmaceutical (000739.SZ): The sustained-release tablets of bupropion hydrochloride (XL) have received PAS approval from the USA FDA.
On January 13, Gelonghui reported that Apeloa Pharmaceutical (000739.SZ) announced that its wholly-owned subsidiary Zhejiang Jutai Pharmaceutical Co., Ltd. has received the approval notification from the USA Food and Drug Administration (referred to as "USA FDA") for the Prior Approval Supplement (PAS) of the hydrochloride bupropion sustained-release tablets (XL) manufacturing site. The hydrochloride bupropion sustained-release tablets (XL) are used to treat depression. This drug is produced by VALEANT INTERNATIONAL BARBADOS SRL.
Hengdian Group Capital and Apeloa Pharmaceutical to Participate in 2025 J.P. Morgan Healthcare Conference
Apeloa Pharmaceutical Gets Approval to Conduct Clinical Trials for Semaglutide Injection; Shares Up 3%
Investors Don't See Light At End Of Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Tunnel
Apeloa Pharmaceutical (000739.SZ): The clinical trial application for Kangyu Pharmaceutical's semaglutide injection for weight management and adult type 2 diabetes indications has been approved.
Gelonghui, January 2nd丨Apeloa Pharmaceutical (000739.SZ) announced that recently, its holding subsidiary Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd. (referred to as "Kangyu Pharmaceutical") received the "Notice of Approval for Clinical Trials" issued by the National Medical Products Administration (Notice Number: 2024LP02958, 2024LP02959, 2024LP02960, 2024LP02961, 2024LP02962, 2024LP02963, 2024LP02964). Kangyu Pharmaceutical applied for the import of semaglutide.
Apeloa PharmaceuticalLtd (SZSE:000739) Investors Are Sitting on a Loss of 50% If They Invested Three Years Ago
Apeloa Pharmaceutical Gets Drug Registration for Influenza Treatment
Apeloa Pharmaceutical (000739.SZ): Kangyu Pharmaceutical has received the pharmaceutical registration certificate for oseltamivir phosphate capsules.
On December 9th, apeloa pharmaceutical (000739.SZ) announced that recently, its wholly-owned subsidiary Zhejiang Puluokangyu Pharmaceutical Co., Ltd. (referred to as "Kangyu Pharmaceutical") received the "Drug Registration Certificate" for oseltamivir phosphate capsules issued by the National Medical Products Administration. Oseltamivir phosphate capsules are used for the treatment of type A and type B influenza in adults and children aged 1 year and older. Patients should use it within 48 hours of the first appearance of symptoms; it is also used for the prevention of type A and type B influenza in adults and adolescents aged 13 years and older. According to relevant data, Oseltamivir phosphate capsules 2
Apeloa Pharmaceutical Signs Strategic Cooperation Framework Deal; Shares Up 3%
Apeloa Pharmaceutical (000739.SZ): signed a global strategy cooperation framework agreement with Jixing Hong Kong.
On November 28th, Gelonhui announced that Apeloa Pharmaceutical (000739.SZ) disclosed that the company ('Party B') and Jixing Pharmaceuticals Hong Kong Limited (referred to as 'Jixing Hong Kong' or 'Party A') recently signed a 'Strategic Cooperation Framework Agreement' based on the principles of equality, mutual benefit, and complementary advantages. The two parties have reached a consensus on the cooperative relationship of the CDMO project, formed a strategic partnership, and will carry out long-term cooperation on the CDMO project.
Apeloa Pharmaceutical Unit Gets China Approval for Bile Flow Injection
Apeloa Pharmaceutical (000739.SZ): Adenosine Diaminesulfonic Acid has obtained the approval notice for the application for listing of chemical raw materials.
On November 21, Gelunhui: Recently, Apeloa Pharmaceutical (000739.SZ) announced that its wholly-owned subsidiary Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd. (hereinafter referred to as "Jiayuan Pharmaceutical") has received the "Chemical Raw Materials Pharmaceutical Market Application Approval Notification Letter" for Adenosine Phosphoric Acid issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"). Adenosine phosphate is a natural physiologically active molecule that exists in all tissues and body fluids, with the highest content in the liver; adenosine phosphate has three major functions: methyl transfer, sulfonyl transfer, and propylamine transfer, participating in important biochemical reactions in the body, helping to prevent bile stasis.
gf sec: The upstream prices of penicillin and cephalosporins are fluctuating at a high level, while the active pharmaceutical ingredient is finding a bottom and stabilizing.
According to the data from the National Bureau of Statistics, in September 2024, the month-on-month PPI value of chemical drug active pharmaceutical ingredient manufacturing was 97.10, an increase of 2.0 compared to the previous month, and an increase of 1.63 from the average of 95.47 in the first half of 2024. Since the year 2023, when the month-on-month PPI of active pharmaceutical ingredient manufacturing fell below 100 for the whole year, the recent PPI value has been in an increasing state, indicating that the overall price of active pharmaceutical ingredients is in a phase of slight bottoming and recovery.